ASPCF News and Press, Acerus Pharmaceuticals Corp From 11/14/19

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three- and nine-month period ended September 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accor...

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB :ASPCF) will announce its third quarter 2019 financial and operating results on Thursday, November 14, 2019 before the market opens. The company will also host a conference call on Thursday, November 14, 2019 at 8:30 a.m. Eastern Time. To...

Current NATESTO ® supply to the United States remains unaffected Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO ® in Canada and South Korea, following the previous announcement of the voluntary...

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the expanded use of NATESTO ® for the treatment of hypogonadism on Wednesday, October 30 th in New York City. The ev...

NATESTO ® shown to significantly increase mean testosterone levels, while maintaining sufficient gonadotropins to preserve fertility Improvement in quality-of-life, overall satisfaction and sexual desire was reported Approximately 65% of men become infertile when presc...

TORONTO , Oct. 17, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO ® Spermatogenesis Study as part of the "Late Breaking" Abstract Session at the 75th Annual American Society for Reproductive ...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter f...

Acerus Pharmaceuticals Corporation (ASPCF) Q2 2019 Earnings Conference Call August 7, 2019 8:30 A.M. ET Company Participants Robert Motz - Chief Financial Officer Edward Gudaitis - President and Chief Executive Officer Conference Call Participants André Uddin - Mackie Re...

Acerus Pharmaceuticals ( OTCQB:ASPCF ): Q2 GAAP EPS of -$0.01. More news on: Acerus Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance w...